Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis Article Swipe
Akinari Tsukada
,
Chie Morita
,
Yosuke Shimizu
,
Yukari Uemura
,
Go Naka
,
Jin Takasaki
,
Hiroshi Nokihara
,
Shinyu Izumi
,
Masayuki Hojo
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1111/1759-7714.15413
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1111/1759-7714.15413
Background Recent advancements in advanced non‐small‐cell lung cancer (NSCLC) treatment have significantly improved primary therapy outcomes owing to the emergence of various molecular targeted therapies and immune checkpoint inhibitors (ICIs). However, for Kirsten rat sarcoma viral antigen (KRAS) mutations, molecular targeted drugs, such as sotorasib, are not applicable as first‐line treatments, and the optimal primary treatment remains unclear. Therefore, we aimed to investigate the efficacy of ICI combination therapy as first‐line treatment for KRAS‐mutant NSCLC. Methods We conducted a systematic search for phase 3 randomized controlled trials (RCTs) that presented data on KRAS mutation status in advanced NSCLC. The primary endpoints were progression‐free survival (PFS) and overall survival (OS). A random‐effects network meta‐analysis was conducted to perform direct and indirect comparisons among treatment groups. Results Six RCTs were eligible for inclusion. In the network meta‐analysis for KRAS‐mutant NSCLC, Chemo + bevacizumab (Bev) + ICI was associated with improved PFS (hazard ratio [HR] 0.38, 95% confidence interval [CI] 0.22–0.64), followed by Chemo + ICI + ICI (HR 0.66, 95% CI 0.47–0.93) and Chemo + ICI (HR 0.67, 95% CI 0.49–0.91). The most beneficial effect on OS was observed with Chemo + Bev + ICI (HR 0.50, 95% CI 0.34–0.73), followed by Chemo + ICI + ICI (HR 0.64, 95% CI 0.48–0.87) and Chemo + ICI (HR 0.72, 95% CI 0.56–0.92). Regarding OS in wild‐type KRAS, ICI + ICI (HR 0.73, 95% CI 0.50–1.07) produced the most favorable effects, followed by Chemo + ICI (HR 0.79, 95% CI 0.63–0.99). Conclusion The efficacy of Chemo + Bev + ICI is potentially high for improving PFS and OS in KRAS‐mutant NSCLC. In advanced NSCLC, the presence or absence of KRAS mutations may need to be considered when administering first‐line treatment.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1111/1759-7714.15413
- OA Status
- gold
- Cited By
- 1
- References
- 24
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4401232022
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4401232022Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/1759-7714.15413Digital Object Identifier
- Title
-
Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysisWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-07-31Full publication date if available
- Authors
-
Akinari Tsukada, Chie Morita, Yosuke Shimizu, Yukari Uemura, Go Naka, Jin Takasaki, Hiroshi Nokihara, Shinyu Izumi, Masayuki HojoList of authors in order
- Landing page
-
https://doi.org/10.1111/1759-7714.15413Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1111/1759-7714.15413Direct OA link when available
- Concepts
-
Medicine, KRAS, Hazard ratio, Bevacizumab, Oncology, Internal medicine, Lung cancer, Combination therapy, Meta-analysis, Confidence interval, Cancer, Chemotherapy, Colorectal cancerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2024: 1Per-year citation counts (last 5 years)
- References (count)
-
24Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4401232022 |
|---|---|
| doi | https://doi.org/10.1111/1759-7714.15413 |
| ids.doi | https://doi.org/10.1111/1759-7714.15413 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39086088 |
| ids.openalex | https://openalex.org/W4401232022 |
| fwci | 0.86262314 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D002289 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[2].qualifier_ui | Q000235 |
| mesh[2].descriptor_ui | D002289 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | genetics |
| mesh[2].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[3].qualifier_ui | Q000473 |
| mesh[3].descriptor_ui | D002289 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | pathology |
| mesh[3].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D000082082 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[5].qualifier_ui | Q000494 |
| mesh[5].descriptor_ui | D000082082 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pharmacology |
| mesh[5].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D008175 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Lung Neoplasms |
| mesh[7].qualifier_ui | Q000235 |
| mesh[7].descriptor_ui | D008175 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | genetics |
| mesh[7].descriptor_name | Lung Neoplasms |
| mesh[8].qualifier_ui | Q000473 |
| mesh[8].descriptor_ui | D008175 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | pathology |
| mesh[8].descriptor_name | Lung Neoplasms |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D009154 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Mutation |
| mesh[10].qualifier_ui | Q000627 |
| mesh[10].descriptor_ui | D020533 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | therapeutic use |
| mesh[10].descriptor_name | Angiogenesis Inhibitors |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000071076 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Network Meta-Analysis |
| mesh[12].qualifier_ui | Q000235 |
| mesh[12].descriptor_ui | D016283 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | genetics |
| mesh[12].descriptor_name | Proto-Oncogene Proteins p21(ras) |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D000971 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[14].qualifier_ui | Q000494 |
| mesh[14].descriptor_ui | D000971 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | pharmacology |
| mesh[14].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D006801 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Humans |
| mesh[16].qualifier_ui | Q000188 |
| mesh[16].descriptor_ui | D002289 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | drug therapy |
| mesh[16].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[17].qualifier_ui | Q000235 |
| mesh[17].descriptor_ui | D002289 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | genetics |
| mesh[17].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[18].qualifier_ui | Q000473 |
| mesh[18].descriptor_ui | D002289 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | pathology |
| mesh[18].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D000082082 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[20].qualifier_ui | Q000494 |
| mesh[20].descriptor_ui | D000082082 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | pharmacology |
| mesh[20].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D008175 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Lung Neoplasms |
| mesh[22].qualifier_ui | Q000235 |
| mesh[22].descriptor_ui | D008175 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | genetics |
| mesh[22].descriptor_name | Lung Neoplasms |
| mesh[23].qualifier_ui | Q000473 |
| mesh[23].descriptor_ui | D008175 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | pathology |
| mesh[23].descriptor_name | Lung Neoplasms |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D009154 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Mutation |
| mesh[25].qualifier_ui | Q000627 |
| mesh[25].descriptor_ui | D020533 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | therapeutic use |
| mesh[25].descriptor_name | Angiogenesis Inhibitors |
| mesh[26].qualifier_ui | Q000235 |
| mesh[26].descriptor_ui | D016283 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | genetics |
| mesh[26].descriptor_name | Proto-Oncogene Proteins p21(ras) |
| mesh[27].qualifier_ui | Q000627 |
| mesh[27].descriptor_ui | D000971 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | therapeutic use |
| mesh[27].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[28].qualifier_ui | Q000494 |
| mesh[28].descriptor_ui | D000971 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | pharmacology |
| mesh[28].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D006801 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Humans |
| mesh[30].qualifier_ui | Q000188 |
| mesh[30].descriptor_ui | D002289 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | drug therapy |
| mesh[30].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[31].qualifier_ui | Q000235 |
| mesh[31].descriptor_ui | D002289 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | genetics |
| mesh[31].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[32].qualifier_ui | Q000473 |
| mesh[32].descriptor_ui | D002289 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | pathology |
| mesh[32].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[33].qualifier_ui | Q000627 |
| mesh[33].descriptor_ui | D000082082 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | therapeutic use |
| mesh[33].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[34].qualifier_ui | Q000494 |
| mesh[34].descriptor_ui | D000082082 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | pharmacology |
| mesh[34].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[35].qualifier_ui | Q000188 |
| mesh[35].descriptor_ui | D008175 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | drug therapy |
| mesh[35].descriptor_name | Lung Neoplasms |
| mesh[36].qualifier_ui | Q000235 |
| mesh[36].descriptor_ui | D008175 |
| mesh[36].is_major_topic | True |
| mesh[36].qualifier_name | genetics |
| mesh[36].descriptor_name | Lung Neoplasms |
| mesh[37].qualifier_ui | Q000473 |
| mesh[37].descriptor_ui | D008175 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | pathology |
| mesh[37].descriptor_name | Lung Neoplasms |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D009154 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Mutation |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D020533 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Angiogenesis Inhibitors |
| mesh[40].qualifier_ui | Q000235 |
| mesh[40].descriptor_ui | D016283 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | genetics |
| mesh[40].descriptor_name | Proto-Oncogene Proteins p21(ras) |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D000971 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[42].qualifier_ui | Q000494 |
| mesh[42].descriptor_ui | D000971 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | pharmacology |
| mesh[42].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D006801 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Humans |
| mesh[44].qualifier_ui | Q000188 |
| mesh[44].descriptor_ui | D002289 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | drug therapy |
| mesh[44].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[45].qualifier_ui | Q000235 |
| mesh[45].descriptor_ui | D002289 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | genetics |
| mesh[45].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[46].qualifier_ui | Q000473 |
| mesh[46].descriptor_ui | D002289 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | pathology |
| mesh[46].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[47].qualifier_ui | Q000627 |
| mesh[47].descriptor_ui | D000082082 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | therapeutic use |
| mesh[47].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[48].qualifier_ui | Q000494 |
| mesh[48].descriptor_ui | D000082082 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | pharmacology |
| mesh[48].descriptor_name | Immune Checkpoint Inhibitors |
| mesh[49].qualifier_ui | Q000188 |
| mesh[49].descriptor_ui | D008175 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | drug therapy |
| mesh[49].descriptor_name | Lung Neoplasms |
| type | review |
| title | Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis |
| biblio.issue | 25 |
| biblio.volume | 15 |
| biblio.last_page | 1862 |
| biblio.first_page | 1854 |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T12334 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9991999864578247 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Lung Cancer Research Studies |
| topics[2].id | https://openalex.org/T10158 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9980999827384949 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Cancer Immunotherapy and Biomarkers |
| is_xpac | False |
| apc_list.value | 2000 |
| apc_list.currency | USD |
| apc_list.value_usd | 2000 |
| apc_paid.value | 2000 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2000 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8749383091926575 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2781187634 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8640053868293762 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q20969980 |
| concepts[1].display_name | KRAS |
| concepts[2].id | https://openalex.org/C207103383 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7670928239822388 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[2].display_name | Hazard ratio |
| concepts[3].id | https://openalex.org/C2777802072 |
| concepts[3].level | 3 |
| concepts[3].score | 0.7335662841796875 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[3].display_name | Bevacizumab |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.7026615738868713 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.6837352514266968 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C2776256026 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5179890394210815 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[6].display_name | Lung cancer |
| concepts[7].id | https://openalex.org/C2776999253 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4464626610279083 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1304270 |
| concepts[7].display_name | Combination therapy |
| concepts[8].id | https://openalex.org/C95190672 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4390047788619995 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q815382 |
| concepts[8].display_name | Meta-analysis |
| concepts[9].id | https://openalex.org/C44249647 |
| concepts[9].level | 2 |
| concepts[9].score | 0.43670204281806946 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[9].display_name | Confidence interval |
| concepts[10].id | https://openalex.org/C121608353 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4150451719760895 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[10].display_name | Cancer |
| concepts[11].id | https://openalex.org/C2776694085 |
| concepts[11].level | 2 |
| concepts[11].score | 0.25471240282058716 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[11].display_name | Chemotherapy |
| concepts[12].id | https://openalex.org/C526805850 |
| concepts[12].level | 3 |
| concepts[12].score | 0.1349969506263733 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q188874 |
| concepts[12].display_name | Colorectal cancer |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8749383091926575 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/kras |
| keywords[1].score | 0.8640053868293762 |
| keywords[1].display_name | KRAS |
| keywords[2].id | https://openalex.org/keywords/hazard-ratio |
| keywords[2].score | 0.7670928239822388 |
| keywords[2].display_name | Hazard ratio |
| keywords[3].id | https://openalex.org/keywords/bevacizumab |
| keywords[3].score | 0.7335662841796875 |
| keywords[3].display_name | Bevacizumab |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.7026615738868713 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.6837352514266968 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/lung-cancer |
| keywords[6].score | 0.5179890394210815 |
| keywords[6].display_name | Lung cancer |
| keywords[7].id | https://openalex.org/keywords/combination-therapy |
| keywords[7].score | 0.4464626610279083 |
| keywords[7].display_name | Combination therapy |
| keywords[8].id | https://openalex.org/keywords/meta-analysis |
| keywords[8].score | 0.4390047788619995 |
| keywords[8].display_name | Meta-analysis |
| keywords[9].id | https://openalex.org/keywords/confidence-interval |
| keywords[9].score | 0.43670204281806946 |
| keywords[9].display_name | Confidence interval |
| keywords[10].id | https://openalex.org/keywords/cancer |
| keywords[10].score | 0.4150451719760895 |
| keywords[10].display_name | Cancer |
| keywords[11].id | https://openalex.org/keywords/chemotherapy |
| keywords[11].score | 0.25471240282058716 |
| keywords[11].display_name | Chemotherapy |
| keywords[12].id | https://openalex.org/keywords/colorectal-cancer |
| keywords[12].score | 0.1349969506263733 |
| keywords[12].display_name | Colorectal cancer |
| language | en |
| locations[0].id | doi:10.1111/1759-7714.15413 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S37904752 |
| locations[0].source.issn | 1759-7706, 1759-7714 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1759-7706 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Thoracic Cancer |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Thoracic Cancer |
| locations[0].landing_page_url | https://doi.org/10.1111/1759-7714.15413 |
| locations[1].id | pmid:39086088 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Thoracic cancer |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39086088 |
| locations[2].id | pmh:oai:doaj.org/article:e9686ee606c04e7b85e9be9001db83ce |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Thoracic Cancer, Vol 15, Iss 25, Pp 1854-1862 (2024) |
| locations[2].landing_page_url | https://doaj.org/article/e9686ee606c04e7b85e9be9001db83ce |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:11367661 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Thorac Cancer |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11367661 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5083392913 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-8582-1964 |
| authorships[0].author.display_name | Akinari Tsukada |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[0].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Akinari Tsukada |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[1].author.id | https://openalex.org/A5023389825 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-0936-9360 |
| authorships[1].author.display_name | Chie Morita |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[1].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Chie Morita |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[2].author.id | https://openalex.org/A5083087923 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9255-3395 |
| authorships[2].author.display_name | Yosuke Shimizu |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[2].affiliations[0].raw_affiliation_string | Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[2].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Yosuke Shimizu |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[3].author.id | https://openalex.org/A5007957984 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3013-7775 |
| authorships[3].author.display_name | Yukari Uemura |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[3].affiliations[0].raw_affiliation_string | Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[3].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Yukari Uemura |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[4].author.id | https://openalex.org/A5050689831 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3804-0898 |
| authorships[4].author.display_name | Go Naka |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[4].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Go Naka |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[5].author.id | https://openalex.org/A5100771036 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-1520-3447 |
| authorships[5].author.display_name | Jin Takasaki |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[5].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Jin Takasaki |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[6].author.id | https://openalex.org/A5020327537 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-1219-6966 |
| authorships[6].author.display_name | Hiroshi Nokihara |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[6].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Hiroshi Nokihara |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[7].author.id | https://openalex.org/A5109465743 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Shinyu Izumi |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[7].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Shinyu Izumi |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[8].author.id | https://openalex.org/A5039492847 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-9595-9657 |
| authorships[8].author.display_name | Masayuki Hojo |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210094012 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I4210094012 |
| authorships[8].institutions[0].ror | https://ror.org/00r9w3j27 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210094012 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | National Center for Global Health and Medicine |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Masayuki Hojo |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1111/1759-7714.15413 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Efficacy of first‐line immune checkpoint inhibitor and anti‐angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen‐mutant advanced non‐small‐cell lung cancer: a systematic review and network meta‐analysis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W3030972949, https://openalex.org/W3142026086, https://openalex.org/W4283712951, https://openalex.org/W4229832877, https://openalex.org/W4306404900, https://openalex.org/W3111812619, https://openalex.org/W4248366929, https://openalex.org/W2028827184, https://openalex.org/W2146312028, https://openalex.org/W2903256743 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2024 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1111/1759-7714.15413 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S37904752 |
| best_oa_location.source.issn | 1759-7706, 1759-7714 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1759-7706 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Thoracic Cancer |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Thoracic Cancer |
| best_oa_location.landing_page_url | https://doi.org/10.1111/1759-7714.15413 |
| primary_location.id | doi:10.1111/1759-7714.15413 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S37904752 |
| primary_location.source.issn | 1759-7706, 1759-7714 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1759-7706 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Thoracic Cancer |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Thoracic Cancer |
| primary_location.landing_page_url | https://doi.org/10.1111/1759-7714.15413 |
| publication_date | 2024-07-31 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3048896255, https://openalex.org/W2251438188, https://openalex.org/W4313398048, https://openalex.org/W3037204750, https://openalex.org/W3190297823, https://openalex.org/W1617328014, https://openalex.org/W2125435699, https://openalex.org/W3203110794, https://openalex.org/W2996463763, https://openalex.org/W2995281612, https://openalex.org/W4307814905, https://openalex.org/W4294944334, https://openalex.org/W4200213413, https://openalex.org/W4213085451, https://openalex.org/W3025429623, https://openalex.org/W3127560436, https://openalex.org/W4382358152, https://openalex.org/W2913235593, https://openalex.org/W2885907209, https://openalex.org/W3020440211, https://openalex.org/W4390061478, https://openalex.org/W2967210753, https://openalex.org/W3007391700, https://openalex.org/W4401232022 |
| referenced_works_count | 24 |
| abstract_inverted_index.+ | 140, 143, 162, 164, 173, 190, 192, 202, 204, 213, 226, 241, 253, 255 |
| abstract_inverted_index.3 | 84 |
| abstract_inverted_index.A | 110 |
| abstract_inverted_index.a | 79 |
| abstract_inverted_index.CI | 169, 178, 197, 209, 218, 231, 246 |
| abstract_inverted_index.In | 132, 268 |
| abstract_inverted_index.OS | 185, 221, 264 |
| abstract_inverted_index.We | 77 |
| abstract_inverted_index.as | 44, 49, 70 |
| abstract_inverted_index.be | 281 |
| abstract_inverted_index.by | 160, 200, 239 |
| abstract_inverted_index.in | 4, 96, 222, 265 |
| abstract_inverted_index.is | 257 |
| abstract_inverted_index.of | 21, 66, 251, 275 |
| abstract_inverted_index.on | 92, 184 |
| abstract_inverted_index.or | 273 |
| abstract_inverted_index.to | 18, 62, 116, 280 |
| abstract_inverted_index.we | 60 |
| abstract_inverted_index.(HR | 166, 175, 194, 206, 215, 228, 243 |
| abstract_inverted_index.95% | 154, 168, 177, 196, 208, 217, 230, 245 |
| abstract_inverted_index.Bev | 191, 254 |
| abstract_inverted_index.ICI | 67, 144, 163, 165, 174, 193, 203, 205, 214, 225, 227, 242, 256 |
| abstract_inverted_index.PFS | 149, 262 |
| abstract_inverted_index.Six | 126 |
| abstract_inverted_index.The | 99, 180, 249 |
| abstract_inverted_index.and | 26, 52, 106, 119, 171, 211, 263 |
| abstract_inverted_index.are | 46 |
| abstract_inverted_index.for | 32, 73, 82, 130, 136, 260 |
| abstract_inverted_index.may | 278 |
| abstract_inverted_index.not | 47 |
| abstract_inverted_index.rat | 34 |
| abstract_inverted_index.the | 19, 53, 64, 133, 234, 271 |
| abstract_inverted_index.was | 114, 145, 186 |
| abstract_inverted_index.KRAS | 93, 276 |
| abstract_inverted_index.RCTs | 127 |
| abstract_inverted_index.[CI] | 157 |
| abstract_inverted_index.[HR] | 152 |
| abstract_inverted_index.data | 91 |
| abstract_inverted_index.have | 11 |
| abstract_inverted_index.high | 259 |
| abstract_inverted_index.lung | 7 |
| abstract_inverted_index.most | 181, 235 |
| abstract_inverted_index.need | 279 |
| abstract_inverted_index.such | 43 |
| abstract_inverted_index.that | 89 |
| abstract_inverted_index.were | 102, 128 |
| abstract_inverted_index.when | 283 |
| abstract_inverted_index.with | 147, 188 |
| abstract_inverted_index.(Bev) | 142 |
| abstract_inverted_index.(OS). | 109 |
| abstract_inverted_index.(PFS) | 105 |
| abstract_inverted_index.0.38, | 153 |
| abstract_inverted_index.0.50, | 195 |
| abstract_inverted_index.0.64, | 207 |
| abstract_inverted_index.0.66, | 167 |
| abstract_inverted_index.0.67, | 176 |
| abstract_inverted_index.0.72, | 216 |
| abstract_inverted_index.0.73, | 229 |
| abstract_inverted_index.0.79, | 244 |
| abstract_inverted_index.Chemo | 139, 161, 172, 189, 201, 212, 240, 252 |
| abstract_inverted_index.KRAS, | 224 |
| abstract_inverted_index.aimed | 61 |
| abstract_inverted_index.among | 122 |
| abstract_inverted_index.owing | 17 |
| abstract_inverted_index.phase | 83 |
| abstract_inverted_index.ratio | 151 |
| abstract_inverted_index.viral | 36 |
| abstract_inverted_index.(KRAS) | 38 |
| abstract_inverted_index.(RCTs) | 88 |
| abstract_inverted_index.NSCLC, | 138, 270 |
| abstract_inverted_index.NSCLC. | 75, 98, 267 |
| abstract_inverted_index.Recent | 2 |
| abstract_inverted_index.cancer | 8 |
| abstract_inverted_index.direct | 118 |
| abstract_inverted_index.drugs, | 42 |
| abstract_inverted_index.effect | 183 |
| abstract_inverted_index.immune | 27 |
| abstract_inverted_index.search | 81 |
| abstract_inverted_index.status | 95 |
| abstract_inverted_index.trials | 87 |
| abstract_inverted_index.(ICIs). | 30 |
| abstract_inverted_index.(NSCLC) | 9 |
| abstract_inverted_index.(hazard | 150 |
| abstract_inverted_index.Kirsten | 33 |
| abstract_inverted_index.Methods | 76 |
| abstract_inverted_index.Results | 125 |
| abstract_inverted_index.absence | 274 |
| abstract_inverted_index.antigen | 37 |
| abstract_inverted_index.groups. | 124 |
| abstract_inverted_index.network | 112, 134 |
| abstract_inverted_index.optimal | 54 |
| abstract_inverted_index.overall | 107 |
| abstract_inverted_index.perform | 117 |
| abstract_inverted_index.primary | 14, 55, 100 |
| abstract_inverted_index.remains | 57 |
| abstract_inverted_index.sarcoma | 35 |
| abstract_inverted_index.therapy | 15, 69 |
| abstract_inverted_index.various | 22 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 31 |
| abstract_inverted_index.advanced | 5, 97, 269 |
| abstract_inverted_index.effects, | 237 |
| abstract_inverted_index.efficacy | 65, 250 |
| abstract_inverted_index.eligible | 129 |
| abstract_inverted_index.followed | 159, 199, 238 |
| abstract_inverted_index.improved | 13, 148 |
| abstract_inverted_index.indirect | 120 |
| abstract_inverted_index.interval | 156 |
| abstract_inverted_index.mutation | 94 |
| abstract_inverted_index.observed | 187 |
| abstract_inverted_index.outcomes | 16 |
| abstract_inverted_index.presence | 272 |
| abstract_inverted_index.produced | 233 |
| abstract_inverted_index.survival | 104, 108 |
| abstract_inverted_index.targeted | 24, 41 |
| abstract_inverted_index.unclear. | 58 |
| abstract_inverted_index.Regarding | 220 |
| abstract_inverted_index.conducted | 78, 115 |
| abstract_inverted_index.emergence | 20 |
| abstract_inverted_index.endpoints | 101 |
| abstract_inverted_index.favorable | 236 |
| abstract_inverted_index.improving | 261 |
| abstract_inverted_index.molecular | 23, 40 |
| abstract_inverted_index.mutations | 277 |
| abstract_inverted_index.presented | 90 |
| abstract_inverted_index.therapies | 25 |
| abstract_inverted_index.treatment | 10, 56, 72, 123 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Conclusion | 248 |
| abstract_inverted_index.Therefore, | 59 |
| abstract_inverted_index.applicable | 48 |
| abstract_inverted_index.associated | 146 |
| abstract_inverted_index.beneficial | 182 |
| abstract_inverted_index.checkpoint | 28 |
| abstract_inverted_index.confidence | 155 |
| abstract_inverted_index.considered | 282 |
| abstract_inverted_index.controlled | 86 |
| abstract_inverted_index.inclusion. | 131 |
| abstract_inverted_index.inhibitors | 29 |
| abstract_inverted_index.mutations, | 39 |
| abstract_inverted_index.randomized | 85 |
| abstract_inverted_index.sotorasib, | 45 |
| abstract_inverted_index.systematic | 80 |
| abstract_inverted_index.treatment. | 286 |
| abstract_inverted_index.bevacizumab | 141 |
| abstract_inverted_index.combination | 68 |
| abstract_inverted_index.comparisons | 121 |
| abstract_inverted_index.investigate | 63 |
| abstract_inverted_index.potentially | 258 |
| abstract_inverted_index.treatments, | 51 |
| abstract_inverted_index.wild‐type | 223 |
| abstract_inverted_index.0.47–0.93) | 170 |
| abstract_inverted_index.0.48–0.87) | 210 |
| abstract_inverted_index.0.50–1.07) | 232 |
| abstract_inverted_index.advancements | 3 |
| abstract_inverted_index.first‐line | 50, 71, 285 |
| abstract_inverted_index.0.22–0.64), | 158 |
| abstract_inverted_index.0.34–0.73), | 198 |
| abstract_inverted_index.0.49–0.91). | 179 |
| abstract_inverted_index.0.56–0.92). | 219 |
| abstract_inverted_index.0.63–0.99). | 247 |
| abstract_inverted_index.KRAS‐mutant | 74, 137, 266 |
| abstract_inverted_index.administering | 284 |
| abstract_inverted_index.significantly | 12 |
| abstract_inverted_index.meta‐analysis | 113, 135 |
| abstract_inverted_index.random‐effects | 111 |
| abstract_inverted_index.non‐small‐cell | 6 |
| abstract_inverted_index.progression‐free | 103 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5083392913 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I4210094012 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.800000011920929 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.69479147 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |